Showing results (91-100 of 183) with videos related to
Sort By:
Pageof 19
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2019
Eight-day Inpatient Directly Observed Therapy for Antiretroviral Therapy (ART) Failure: A Tool For Preventing Unnecessary ART Changes and Optimizing Adherence SupportNicole E Winchester, Frank Maldarelli, Yolanda Mejia, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 25, 2011
CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7Marta Catalfamo, Christopher Wilhelm, Lueng Tcheung, et al.BMC Infectious Diseases|January 22, 2022
The 6-minute walk test predicts mortality in a pulmonary nontuberculous mycobacteria-predominant bronchiectasis cohortRebekah A Blakney, Emily E Ricotta, Dean Follmann, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2008
Contribution of TCR-beta locus and HLA to the shape of the mature human Vbeta repertoireJ Joseph Melenhorst, Matthew D H Lay, David A Price, et al.Emerging Infectious Diseases|July 25, 2022
Incidence of Nontuberculous Mycobacterial Pulmonary Infection, by Ethnic Group, Hawaii, USA, 2005-2019Rebekah A Blakney, Emily E Ricotta, Timothy B Frankland, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2015
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)Scott R Evans, Daniel Rubin, Dean Follmann, et al.Medrxiv : the Preprint Server for Health Sciences|May 7, 2025
Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM SyndromeDavid H McDermott, Shamik Majumdar, Daniel Velez, et al.Journal of Virological Methods|February 27, 2018
Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assayJames Logue, Kaylie Tuznik, Dean Follmann, et al.Annals of Internal Medicine|July 5, 2022
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical TrialDean Follmann, Holly E Janes, Olive D Buhule, et al.Biostatistics (Oxford, England)|June 22, 2025
A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine developmentPeter B Gilbert, James Peng, Larry Han, et al.Pageof 19